Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering (IMRX) reported updated Phase 2a data at ASCO for atebimetinib plus modified gemcitabine/nab-paclitaxel in 55 first-line metastatic pancreatic cancer patients. Median overall survival was 17.3 months vs 8.5 months in the MPACT standard-of-care study, with 8.3-month PFS, 82% disease control, and 36% ORR. Grade 3+ treatment-related AEs were limited to two chemotherapy-related categories; 84% maintained/gained weight at 3 months. MAPKeeper 301 Phase 3 is recruiting, with first dosing ex
How this was made
The 30-second read
Why it matters
The expanded cohort’s survival and safety/tolerability profile is a meaningful clinical update that can re-rate expectations for MAPKeeper 301, the randomized Phase 3 trial whose primary endpoint is overall survival.
Market read
Fresh expanded Phase 2a efficacy/safety datapoints plus an immediate investor call create a tradable catalyst window for IMRX, with Phase 3 still the key validation step.
What to watch
Key uncertainties remain around effect size versus SOC in a randomized setting, patient selection/biomarker irrelevance (“irrespective of mutational status”), and how tolerability impacts dose intensity in practice.
Background
IMRX is advancing atebimetinib, a Deep Cyclic Inhibitor of MEK, in first-line metastatic pancreatic ductal adenocarcinoma with modified gemcitabine/nab-paclitaxel (mGnP).
Ticker impact
Immuneering reported expanded Phase 2a ASCO data for atebimetinib+mGnP, showing 17.3-month median OS and favorable Grade 3+ tolerability.
Near-term upside bias possible on biotech momentum, but magnitude likely tempered by single-arm Phase 2 nature and lack of Phase 3 results.
The article provides fresh, quantified clinical datapoints (expanded cohort OS/PFS/ORR and adverse-event profile) plus an active Phase 3 recruiting timeline and an investor call today, which can drive trading interest.
Market effects
Reinforces investor appetite for targeted MEK/Deep Cyclic Inhibitor strategies in RAS/RAF-driven oncology and for chemo-combination regimens in pancreatic cancer.
Primarily US biotech/oncology sentiment; ASCO timing can spill over to other pancreatic cancer and clinical-stage oncology names.
Pancreatic cancer efficacy/tolerability read-through can influence global clinical-trial expectations and competitive positioning, though no direct competitor-specific catalyst is cited.
Counterpoint
Single-arm Phase 2a results (even with a historical comparator) may not translate to randomized Phase 3 efficacy; adverse-event rates are limited but still chemotherapy-driven.
Key entities
- companyImmuneering Corporation
Nasdaq-listed late-stage clinical oncology company presenting updated Phase 2a atebimetinib+mGnP data at ASCO and recruiting Phase 3 MAPKeeper 301.
- drugAtebimetinib
Investigational oral, once-daily MEK Deep Cyclic Inhibitor evaluated in combination with mGnP for first-line metastatic pancreatic cancer.
- clinical_trialMAPKeeper 301 (NCT07562152)
Global randomized Phase 3 trial of atebimetinib+mGnP vs standard-of-care gemcitabine/nab-paclitaxel; recruiting with first dosing expected mid-2026.
